Title |
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
|
---|---|
Published in |
Clinical Gastroenterology and Hepatology, February 2014
|
DOI | 10.1016/j.cgh.2014.02.024 |
Pubmed ID | |
Authors |
Veronique S. Chachay, Graeme A. Macdonald, Jennifer H. Martin, Jonathan P. Whitehead, Trisha M. O'Moore–Sullivan, Paul Lee, Michael Franklin, Kerenaftali Klein, Paul J. Taylor, Maree Ferguson, Jeff S. Coombes, Gethin P. Thomas, Gary J. Cowin, Carl M.J. Kirkpatrick, Johannes B. Prins, Ingrid J. Hickman |
Abstract |
Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity, insulin resistance, and inflammation. Although weight loss via calorie restriction reduces features of NAFLD, there is no pharmacologic therapy. Resveratrol is a polyphenol that prevents high-energy diet-induced steatosis and insulin resistance in animals by up-regulating pathways that regulate energy metabolism. We performed a placebo-controlled trial to assess the effects of resveratrol in patients with NAFLD. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 25% |
Spain | 1 | 25% |
United States | 1 | 25% |
Italy | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 50% |
Scientists | 1 | 25% |
Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | <1% |
Italy | 1 | <1% |
Unknown | 206 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 41 | 20% |
Student > Master | 33 | 16% |
Researcher | 23 | 11% |
Student > Ph. D. Student | 22 | 11% |
Student > Postgraduate | 11 | 5% |
Other | 32 | 15% |
Unknown | 46 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 52 | 25% |
Biochemistry, Genetics and Molecular Biology | 18 | 9% |
Agricultural and Biological Sciences | 18 | 9% |
Nursing and Health Professions | 16 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 11 | 5% |
Other | 32 | 15% |
Unknown | 61 | 29% |